TrioxBio Inc., a Delaware Corporation, is a clinical-stage biotech company specializing in the development of compounds to treat diseases and medical conditions related to the pathological overproduction of Nitric Oxide (NO).

Over 100 white papers and articles have been published documenting how the overproduction of nitric oxide is linked to harmful effects on the human body and strongly believed to be responsible for numerous medical conditions, such as migraine, cluster headache, intradialytic hypotension and vasoplegic syndrome, two examples of severe hypotension.

TrioxBio's top candidate, S-ethylisothiouronium diethylphosphate, MTR-104, is a Nitric Oxide Synthase (NOS) inhibitor which blocks the production of nitric oxide, preventing the dilation of blood vessels and the other detrimental effects caused by excessive NOS activity.

Our mission is our commitment to improving quality of life. By way of our existing products and pending approvals across our various markets, our aim is to provide patients with better access to high-quality, cost-effective medicines in key therapeutic areas.

News & Media

 August 29, 2016:

"The FDA's Office of Orphan Products Development granted TrioxBio Inc. its orphan-drug designation request of S-ethylisothiouronium diethylphosphate (MTR-107) for treatment of chronic or recurrent symptomatic intradialytic hypotension (IDH) including symptomatic hypotension in the immediate post-dialytic period."

January 17, 2016:

" TrioxBio Inc. submitted  an Orphan-drug designation request to FDA authorities for the treatment of chronic or recurrent symptomatic intradialytic hypotension (IDH)."